There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (NASDAQ:JAZZ) and Cytosorbents Corp (NASDAQ:CTSO) with bullish sentiments.
Jazz Pharmaceuticals (JAZZ)
In a report released yesterday, David Buck from B.Riley FBR reiterated a Buy rating on Jazz Pharmaceuticals, with a price target of $219. The company’s shares opened today at $169.84.
Buck said:
“We reiterate our Buy rating for Jazz Pharmaceuticals plc (JAZZ), our top pick and Alpha Generator name. Our price target remains $219 per share and we see Jazz shares as particularly attractive after correcting by 3.7% for week ended 8/24/18 versus its benchmark gaining 0.5%. BMO this morning, 8/27, the company announced EU approval for Vyeos in varied subtypes of high-risk AML with the Vyxeos (44mg/100mg powder for solution) approval covering all EU member states plus a few add-on European countries. We expect rolling EU launches following pricing and reimbursement decisions on a country-by-country basis. This approval is slightly ahead of our September 2018 expectation. As reminder JAZZ guidance for Vyxeos moved down post 2Q18 results from $130M-$155M to $115M-$135M.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 14.1% and a 74.4% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $201.85, which is a 18.8% upside from current levels. In a report issued on August 15, Wells Fargo also maintained a Buy rating on the stock with a $195 price target.
.
See today’s analyst top recommended stocks >>
Cytosorbents Corp (CTSO)
In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on Cytosorbents Corp, with a price target of $16.50. The company’s shares opened today at $12.85, close to its 52-week high of $13.80.
D’silva noted:
“We were expecting these approvals (see note dated 1/25/18) and believe they represent an overlooked catalyst for CytoSorbents Corporation (CTSO), as it positions CytoSorb (CS) to be utilized alongside CAR-T therapy in Europe as a potential solution for cytokine release syndrome (CRS), which is an adverse immune response induced from the emerging treatment class. We view the approval the EC as meaningful milestones for CTSO as the company already received CE Mark approval for CS in clinical cases for indications where cytokine levels are elevated. CTSO even obtained a dedicated reimbursement code for CS in Germany, which is the largest healthcare market in Europe.”
According to TipRanks.com, D’silva is a 5-star analyst with an average return of 25.8% and a 54.8% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc., Cytori Therapeutics Inc, and Oramed Pharmaceuticals.
Cytosorbents Corp has an analyst consensus of Strong Buy, with a price target consensus of $16.13, implying a 25.5% upside from current levels. In a report issued on August 16, Maxim Group also maintained a Buy rating on the stock with a $18 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
